AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6213126 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of verapamil (single dose of 80 mg)
Number of subjects: 15
Study 6213126 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of verapamil (single dose of 10 mg in 45 minutes)
Number of subjects: 15
Study 6213126 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 15
Study 30883748 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronally Advanced Flap (CAF)
Number of subjects: 36
Study 30883748 — intervention group
Group type: EXPERIMENTAL
Intervention: Laterally Positioned Flap (LPF)
Number of subjects: 36
Study 27017157 — intervention group
Group type: EXPERIMENTAL
Intervention: External task‐focused facilitation
Number of subjects: 10
Study 27017157 — intervention group
Group type: COMPARATOR
Intervention: Usual practice
Number of subjects: 10
Study 26018599 — intervention group
Group type: EXPERIMENTAL
Intervention: ReCharge ice cream (100g for 2 weeks before and 6 weeks after chemotherapy)
Number of subjects: 197
Study 26018599 — intervention group
Group type: EXPERIMENTAL
Intervention: ReCharge ice cream
Number of subjects: 197
Study 26018599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study 24480604 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo holding (1h of daily skin-to-skin contact on the chest of mother)
Number of subjects: 79
Study 24480604 — intervention group
Group type: EXPERIMENTAL
Intervention: Blanket holding (dressed and held in mother's arms)
Number of subjects: 79
Study 24480604 — intervention group
Group type: COMPARATOR
Intervention: Control group (no holding restrictions, received weekly brief social visits)
Number of subjects: 79
Study 21540805 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 40 mg bolus injection
Number of subjects: 71
Study 21540805 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 71
Study 19417232 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT)
Number of subjects: 10
Study 19417232 — intervention group
Group type: COMPARATOR
Intervention: Traditional rowing training (CT)
Number of subjects: 10
Study 17285368 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallbladder aspiration before dissection (Group A, n = 100)
Number of subjects: 200
Study 17285368 — intervention group
Group type: COMPARATOR
Intervention: No gallbladder aspiration (Group B, n = 100)
Number of subjects: 200
Study 15528034 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (1 g/d for a week)
Number of subjects: 7
Study 15528034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 15528034 — intervention group
Group type: EXPERIMENTAL
Intervention: Diving apnea (both groups)
Number of subjects: 7
Study 11182045 — intervention group
Group type: EXPERIMENTAL
Intervention: Biafine
Number of subjects: 74
Study 11182045 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipiderm
Number of subjects: 74
Study 11182045 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 74
Study 9512083 — intervention group
Group type: EXPERIMENTAL
Intervention: HP 228 (30 microg/kg)
Number of subjects: 6
Study 9512083 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (0.15 mg/kg)
Number of subjects: 6
Study 9512083 — intervention group
Group type: EXPERIMENTAL
Intervention: HP 228 (30 microg/kg) plus Morphine (0.15 mg/kg)
Number of subjects: 6
Study 9512083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 8062152 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microgram of 1 alpha(OH)D3 daily
Number of subjects: 80
Study 8062152 — intervention group
Group type: COMPARATOR
Intervention: Inactive placebo
Number of subjects: 80
Study 2543199 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 60
Study 2543199 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 60
Study 2543199 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 60
Study 2543199 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 60
Study 29330101 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based weight loss support (6-month program)
Number of subjects: 120
Study 29330101 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 120
Study 26866508 — intervention group
Group type: EXPERIMENTAL
Intervention: sorghum biscuits
Number of subjects: 40
Study 26866508 — intervention group
Group type: COMPARATOR
Intervention: wheat control
Number of subjects: 40
Study 25633911 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (IG) - outpatient (unsupervised) cardiac rehabilitation (CR) primarily centered on a progressive walking program
Number of subjects: 88
Study 25633911 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - usual care
Number of subjects: 88
Study 24344445 — intervention group
Group type: EXPERIMENTAL
Intervention: ADVATE (recombinant anti‐hemophilic factor VIII, plasma‐free method [octocog alfa])
Number of subjects: 850
Study 20937116 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise test (CPET)
Number of subjects: 15
Study 20937116 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma creatine kinase (CK) levels
Number of subjects: 15
Study 18216512 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprathel
Number of subjects: 30
Study 18216512 — intervention group
Group type: COMPARATOR
Intervention: Omiderm
Number of subjects: 30
Study 16214634 — intervention group
Group type: EXPERIMENTAL
Intervention: Titrated oral appliance
Number of subjects: 14
Study 12360125 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization (n = 23)
Number of subjects: 56
Study 12360125 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy (n = 33)
Number of subjects: 56
Study 9989538 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous doxycycline (100 mg every 12 hours)
Number of subjects: 87
Study 9989538 — intervention group
Group type: COMPARATOR
Intervention: Control group (other antibiotic regimens)
Number of subjects: 87
Study 7760260 — intervention group
Group type: EXPERIMENTAL
Intervention: Honest responding (N = 62)
Number of subjects: 178
Study 7760260 — intervention group
Group type: COMPARATOR
Intervention: Defensive responding (N = 62)
Number of subjects: 178
Study 7760260 — intervention group
Group type: COMPARATOR
Intervention: Forensic subjects suspected of abusing psychoactive substances (N = 54)
Number of subjects: 178
Study 2271433 — intervention group
Group type: EXPERIMENTAL
Intervention: Yellow fever vaccine
Number of subjects: 77
Study 7246701 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral hypotonic tear preparations
Number of subjects: 15
Study 7246701 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic or near‐isotonic alkaline tear substitutes
Number of subjects: 15
Study 31546576 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt reduced bread
Number of subjects: 120
Study 31546576 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt reduced bread and dietary counseling
Number of subjects: 120
Study 31546576 — intervention group
Group type: COMPARATOR
Intervention: Standard bread
Number of subjects: 120
Study 28158963 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy
Number of subjects: 100
Study 28158963 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 100
Study 25854932 — intervention group
Group type: EXPERIMENTAL
Intervention: Bushen Capsule (BSC), orally treated for 3 months
Number of subjects: 44
Study 25854932 — intervention group
Group type: COMPARATOR
Intervention: Placebo, treated for 3 months
Number of subjects: 44
Study 24074830 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibular fixation using a 3.5‐mm Limited Contact Dynamic Compression Plate (LC‐DCP)
Number of subjects: 60
Study 24074830 — intervention group
Group type: COMPARATOR
Intervention: Interlocking nailing of the tibia without fibular fixation
Number of subjects: 60
Study 24074830 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 60
Study 21843690 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized computer-based intervention
Number of subjects: 463
Study 21843690 — intervention group
Group type: COMPARATOR
Intervention: Enhanced standard care counseling intervention
Number of subjects: 463
Study 19484669 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulization and non-invasive positive pressure with IPAP = 15 cm H(2)O and EPAP = 10 cm H(2)O (Experimental Group 2)
Number of subjects: 36
Study 19484669 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulization and non-invasive positive pressure with IPAP = 15 cm H(2)O and EPAP = 5 cm H(2)O (Experimental Group 1)
Number of subjects: 36
Study 19484669 — intervention group
Group type: COMPARATOR
Intervention: Nebulization with the use of an unpressured mask (Control Group)
Number of subjects: 36
Study 17259189 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated instant coffee (629 women)
Number of subjects: 1207
Study 17259189 — intervention group
Group type: COMPARATOR
Intervention: Caffeinated instant coffee (568 women)
Number of subjects: 1207
Study 15474548 — intervention group
Group type: EXPERIMENTAL
Intervention: Easy cell phone conversation
Number of subjects: 0
Study 15474548 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficult cell phone conversation
Number of subjects: 0
Study 15474548 — intervention group
Group type: COMPARATOR
Intervention: No cell phone conversation (implied control)
Number of subjects: 0
Study 12499031 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microg ethinylestradiol/150 microg levonorgestrel (LNG)
Number of subjects: 140
Study 12499031 — intervention group
Group type: COMPARATOR
Intervention: 35 microg ethinylestradiol/250 microg norgestimate (NGM)
Number of subjects: 140
Study 9879695 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical parameters (age, degree of coma, reflex changes)
Number of subjects: 28
Study 9879695 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory parameters (CSF cell and protein content, haemagglutination inhibition titre)
Number of subjects: 28
Study 9879695 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurophysiological parameters (EEG, EMG, sensory and motor evoked potentials)
Number of subjects: 28
Study 9879695 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiological changes
Number of subjects: 28
Study 8021910 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine coat core 30 mg once daily
Number of subjects: 19
Study 8021910 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine coat core 60 mg once daily
Number of subjects: 19
Study 8021910 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine coat core (both doses)
Number of subjects: 19
Study 3415882 — intervention group
Group type: EXPERIMENTAL
Intervention: Premedication with diazepam 0.14 mg kg‐1 by mouth
Number of subjects: 8
Study 3415882 — intervention group
Group type: EXPERIMENTAL
Intervention: Premedication with hyoscine 6 micrograms kg‐1 + morphine 0.2 mg kg‐1 i.m.
Number of subjects: 8
Study 3415882 — intervention group
Group type: COMPARATOR
Intervention: No premedication
Number of subjects: 8
Study 3415882 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine 1 mg kg‐1 rapid i.v. injection
Number of subjects: 8
Study 3415882 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of AAG and albumin plasma protein fractions
Number of subjects: 8
Study 31667572 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab monotherapy (arm A)
Number of subjects: 78
Study 31667572 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab plus mono-chemo-agent (arm B)
Number of subjects: 78
Study 29228386 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution-Focused Brief Therapy (SFBT)
Number of subjects: 40
Study 29228386 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 40
Study 28738912 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted lifestyle intervention (7 group sessions over 4 months)
Number of subjects: 96
Study 25967354 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment for 2 years
Number of subjects: 0
Study 25967354 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (SHOX-D)
Number of subjects: 0
Study 25967354 — intervention group
Group type: EXPERIMENTAL
Intervention: GH-treated group (TS)
Number of subjects: 0
Study 23743310 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 months of isoniazid
Number of subjects: 215
Study 23743310 — intervention group
Group type: COMPARATOR
Intervention: 4 months of rifampicin
Number of subjects: 215
Study 21255526 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 5 μg
Number of subjects: 30
Study 21255526 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 10 μg
Number of subjects: 30
Study 21255526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 21255526 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (both doses)
Number of subjects: 30
Study 19451281 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amikacin 500 mg by inhalation once daily for 14 days
Number of subjects: 24
Study 16815138 — intervention group
Group type: EXPERIMENTAL
Intervention: House dust mite (HDM) avoidance
Number of subjects: 616
Study 16815138 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary modification
Number of subjects: 616
Study 16815138 — intervention group
Group type: COMPARATOR
Intervention: Control group for HDM avoidance
Number of subjects: 616
Study 16815138 — intervention group
Group type: COMPARATOR
Intervention: Control group for dietary modification
Number of subjects: 616
Study 14688521 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase preflush
Number of subjects: 30
Study 14688521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 11125606 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac administered preoperatively (n = 25)
Number of subjects: 49
Study 11125606 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac administered at the conclusion of surgery (Control group, n = 24)
Number of subjects: 49
Study 11125606 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of pain scores using M-VAS
Number of subjects: 49
Study 11125606 — intervention group
Group type: EXPERIMENTAL
Intervention: Total fentanyl use and postoperative oral analgesic requirements
Number of subjects: 49
Study 9166164 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin-sulbactam for 72 hours followed by amoxicillin-clavulanate
Number of subjects: 112
Study 9166164 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin for 72 hours followed by amoxicillin
Number of subjects: 112
Study 9166164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 8222197 — intervention group
Group type: EXPERIMENTAL
Intervention: Carpentier‐Edwards (C‐E) valve
Number of subjects: 174
Study 8222197 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic Hancock I (H) valve
Number of subjects: 174
Study 2892047 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium 500 mg plus intranasal salmon calcitonin 50 IU/day for 5 days per week
Number of subjects: 79
Study 2892047 — intervention group
Group type: COMPARATOR
Intervention: Calcium 500 mg/day
Number of subjects: 79
Study 25766052 — intervention group
Group type: EXPERIMENTAL
Intervention: Static hamstring stretching (4 exercises, 30 seconds each, performed twice with 15 seconds rest, 6 days per week for 7 weeks)
Number of subjects: 103
Study 25766052 — intervention group
Group type: EXPERIMENTAL
Intervention: Static hamstring stretching
Number of subjects: 103
Study 25766052 — intervention group
Group type: COMPARATOR
Intervention: Control group (no stretching)
Number of subjects: 103
Study 25613431 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 100 mg
Number of subjects: 117
Study 25613431 — intervention group
Group type: COMPARATOR
Intervention: No losartan
Number of subjects: 117
Study 23622915 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential medical therapy before PCI
Number of subjects: 60386
Study 23622915 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential medical therapy at discharge after PCI
Number of subjects: 60386
Study 23622915 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin use before PCI
Number of subjects: 60386
Study 23622915 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin use after PCI
Number of subjects: 60386
Study 23622915 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use before PCI
Number of subjects: 60386
Study 23622915 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use after PCI
Number of subjects: 60386
Study 23622915 — intervention group
Group type: EXPERIMENTAL
Intervention: β-Blocker use before PCI
Number of subjects: 60386
Study 23622915 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel use after PCI
Number of subjects: 60386
Study 23622915 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy comparison based on history of myocardial infarction or revascularization before PCI
Number of subjects: 60386
Study 23622915 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy likelihood based on gender and dialysis status
Number of subjects: 60386
Study 20564933 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (4 mg/kg/hr) + Ketamine (2 mg/kg/hr)
Number of subjects: 0
Study 20564933 — intervention group
Group type: COMPARATOR
Intervention: Propofol (4 mg/kg/hr) + Fentanyl (3 microg/kg/hr)
Number of subjects: 0
Study 18230942 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 125
Study 18230942 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Writing Therapy (SWT)
Number of subjects: 125
Study 18230942 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 125
Study 20675425 — intervention group
Group type: EXPERIMENTAL
Intervention: NovaMin powder with NovaMin‐containing toothpaste (group 1)
Number of subjects: 60
Study 20675425 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo powder with NovaMin‐containing toothpaste (group 2)
Number of subjects: 60
Study 20675425 — intervention group
Group type: COMPARATOR
Intervention: Placebo powder with desensitizing toothpaste containing potassium nitrate (group 3)
Number of subjects: 60
Study 16390769 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 156
Study 16390769 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 156
Study 11135090 — intervention group
Group type: EXPERIMENTAL
Intervention: New PD fluid
Number of subjects: 80
Study 11135090 — intervention group
Group type: COMPARATOR
Intervention: Conventional PD fluid
Number of subjects: 80
Study 9587114 — intervention group
Group type: EXPERIMENTAL
Intervention: Telomerase activity in hepatocellular carcinoma (HCC)
Number of subjects: 44
Study 9587114 — intervention group
Group type: COMPARATOR
Intervention: Telomerase activity in cirrhotic liver samples
Number of subjects: 44
Study 9587114 — intervention group
Group type: COMPARATOR
Intervention: Telomerase activity in large noncancerous nodules
Number of subjects: 44
Study 9587114 — intervention group
Group type: COMPARATOR
Intervention: Telomerase activity in large regenerative nodules
Number of subjects: 44
Study 7785204 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced physical training
Number of subjects: 134
Study 7785204 — intervention group
Group type: COMPARATOR
Intervention: Traditional rehabilitation (controls)
Number of subjects: 134
Study 2457523 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 56
Study 2457523 — intervention group
Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 56
Study 2457523 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 56
Study 31146028 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based simulator training of spatial skills
Number of subjects: 41
Study 31146028 — intervention group
Group type: COMPARATOR
Intervention: Neutral activity (control group)
Number of subjects: 41
Study 30666799 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib
Number of subjects: 294
Study 30666799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 294
Study 28910811 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training for 12 weeks
Number of subjects: 39
Study 28910811 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 39
Study 26948519 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger (500 mg)
Number of subjects: 60
Study 26948519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 25188700 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU+EMDR
Number of subjects: 12
Study 25188700 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 12
Study 22038079 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 813
Study 22038079 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 813
Study 18204981 — intervention group
Group type: EXPERIMENTAL
Intervention: alteplase infusion plus weight-adjusted UH (24-48 h) and then enoxaparin (7 days)
Number of subjects: 80
Study 18204981 — intervention group
Group type: EXPERIMENTAL
Intervention: enoxaparin
Number of subjects: 80
Study 18204981 — intervention group
Group type: COMPARATOR
Intervention: UH standard regimen
Number of subjects: 80
Study 17688686 — intervention group
Group type: EXPERIMENTAL
Intervention: O. niloticus (larvivorous fish) introduced into treated ponds
Number of subjects: 0
Study 17688686 — intervention group
Group type: COMPARATOR
Intervention: Control pond (untreated)
Number of subjects: 0
Study 15506870 — intervention group
Group type: EXPERIMENTAL
Intervention: Work sharing policy
Number of subjects: 0
Study 15506870 — intervention group
Group type: COMPARATOR
Intervention: Fixed assignment policy
Number of subjects: 0
Study 11513446 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine (5 mg three times a day, increased to 15 mg three times a day as needed)
Number of subjects: 61
Study 11513446 — intervention group
Group type: COMPARATOR
Intervention: Fluid therapy (increased fluid intake, salt tablets, and counseling)
Number of subjects: 61
Study 9591742 — intervention group
Group type: EXPERIMENTAL
Intervention: High-stearic acid diet
Number of subjects: 15